Blood · 2000 · 29 citations · 33 references
Life SciencesCell BiologyOncologyApoptosisMolecular OncologyOncogenesApoptosis In CancerApoptosis RegulationBcl-2 Family ProteinsCancer CytogeneticsMyelodysplastic SyndromesMyeloid-derived Suppressor CellsAcute Myeloid Leukemia BiologyBcl-2 Family DysregulationBcl-2 Protein ExpressionBcl-2 Protein RegulationPro-apoptotic Bcl-2 ProteinsProapoptotic Bcl-2 ProteinsRegulation By Bcl-2 Family Proteins
Bone marrow CD34+ cell apoptosis (annexin V), proliferation (Ki-67), and Bcl-2-related protein expression was evaluated by flow cytometry in 102 patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia secondary to MDS (MDS-AML) and in 30 normal donors (NBM). Apoptosis was significantly increased in refractory anemia (RA)/RA with ringed sideroblasts (RARS) (56.9% [20.4%-93.6%]) and refractory anemia with excess blasts (RAEB) (51.2% [25.2%-76.6%]) compared with NBM (16.7% [3.4%-35.3%],P < .0001). In RA/RARS, apoptosis always exceeded proliferation (Ki-67-positivity, 26.1% [9.5%-47.8%]; apoptosis:proliferation ratio 2.08 [1.15-3.63]); whereas in RAEB, this ratio equalized (1.14 [0.93-2.08]) due to increased proliferation (40.4% [22%-69.5%]). Progression to RAEB in transformation (RAEB-t)/MDS-AML was associated with a significant reduction in apoptosis (22.3% [2.1%-53.2%];P < .0001) and proliferation (16.8% [1.9%-75.8%);P = .04; ratio 1.69 [0.16-12.21]). Pro-apoptotic (Bax/Bad) versus anti-apoptotic (Bcl-2/Bcl-X) Bcl-2-related protein ratios were increased in RA/RARS compared with NBM (2.57 [1.93-9.42] versus 1.89 [0.65-4.1]; P = .06), whereas disease progression was associated with significantly reduced ratios (1.16 [0.06-3.32]; P < .0001) due primarily to increased Bcl-2 expression. Apoptosis and Bax/Bad:Bcl-2/Bcl-X ratio were inversely correlated with both International Prognostic Scoring System score and cytogenetic risk group; highest levels observed in patients with low score and/or good risk cytogenetics. There was a trend toward an association between Bcl-2–related protein expression and apoptosis (P = .07). This study indicates that MDS progression arises through multiple hits that alter levels of CD34+cell apoptosis and proliferation. Early disease is associated with excessive apoptosis and elevated ratio of apoptosis to proliferation. Increased proliferative rates are observed in RAEB, whereas leukemic transformation arises through inhibition of apoptosis rather than excessive cell growth. Although disease progression is accompanied by a fall in pro-apoptotic versus anti-apoptotic Bcl-2–related protein ratios, heterogeneity in patterns of protein expression indicates that factors additional to Bcl-2 family members play a role in the deregulated apoptosis in MDS.
33
I. Vermes, C. Haanen, H M Steffens-Nakken et al. · Journal of Immunological Methods · 1995 · 5.4K citations · Full text
International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes
Peter L. Greenberg, Christopher Cox, Michelle M. LeBeau et al. · Blood · 1997 · 4.5K citations · Full text
Proposals for the classification of the myelodysplastic syndromes
John M. Bennett, Daniel Catovsky, MT Daniel et al. · British Journal of Haematology · 1982 · 3.7K citations
Medicine, Hematology, Pathology +12
Séamus J. Martin, Chris Reutelingsperger, Anne J. McGahon et al. · The Journal of Experimental Medicine · 1995 · 2.9K citations · Full text